Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794662 | 1.00 | KCNQ3 (0.51) | KCNQ3KCNQ2MAPK1TP53PDE10A | |
| SCHEMBL15478170 | 0.94 | KCNQ3 (0.47) | KCNQ3KCNQ2MAPK1TP53PDE10A | |
| SCHEMBL22337 | 0.92 | KCNQ3 (0.46) | KCNQ3KCNQ2MAPK1TP53PDE10A | |
| SCHEMBL30795312 | 0.92 | KCNQ3 (0.46) | KCNQ3KCNQ2MAPK1TP53PDE10A | |
| SCHEMBL23281 | 0.92 | KCNQ3 (0.48) | KCNQ3KCNQ2MAPK1TP53PDE10A | |
| SCHEMBL30795638 | 0.92 | KCNQ3 (0.48) | KCNQ3KCNQ2MAPK1TP53PDE10A | |
| SCHEMBL21737 | 0.90 | KCNQ3 (0.62) | KCNQ3KCNQ2TP53MAPTADORA2A | |
| SCHEMBL30795749 | 0.90 | KCNQ3 (0.62) | KCNQ3KCNQ2TP53MAPTADORA2A | |
| SCHEMBL20971 | 0.90 | KCNQ3 (0.44) | KCNQ3KCNQ2MAPK1TP53PDE10A | |
| SCHEMBL20473 | 0.90 | MMP13 (0.47) | KCNQ3KCNQ2MAPK1TP53PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609083-B1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-02-25 | — | — | EP | claimed |
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2014-03-20 | — | — | US | claimed |
| US-8653101-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2014-02-18 | — | — | US | claimed |
| EP-2609083-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025236-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | claimed |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2012-03-01 | — | — | US | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-9073862-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2609083-B1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2014-03-20 | — | — | US | disclosed |
| US-8653101-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2609083-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2012025236-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | KCNQ3 3/4885KCNQ2 2/4885MAPK1 1945/4885 |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | KCNQ3 3/4885KCNQ2 2/4885MAPK1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.